# Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT01746849** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 82 (actual)

## Conditions studied

- Leukemia
- Multiple Myeloma
- Myelodysplastic Syndrome
- Non-Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** Palifermin
- **BIOLOGICAL:** Lupron
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** Total-Body Irradiation (TBI)
- **DRUG:** Thiotepa
- **DRUG:** Cyclophosphamide
- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT01746849
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-12
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2026-01-07

## Collaborators

- Swedish Orphan Biovitrum

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01746849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01746849, "Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT01746849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*